UK383367 (also known as UK-383,367 or AS-604850) is a potent and selective inhibitor of p38 MAP kinase, which is involved in various cellular processes such as inflammation, cell proliferation, differentiation, and apoptosis. This product has potential therapeutic applications in the treatment of inflammatory diseases, cancer, and neurodegenerative disorders.
The chemical name of UK383367 is 4-(4-Fluorophenyl)-2-(4-methylsulfonylphenyl)-5-(4-pyridyl)imidazole.
Top Ten Keywords from Google and Synonyms:
Health Benefits of this Product:
UK383367 is still undergoing preclinical studies for potential therapeutic benefits in humans. However, some studies have shown that it may have health benefits in treating certain diseases. For example, it was found to have a therapeutic effect on the symptoms of rheumatoid arthritis, asthma, and fibrotic lung disease in animal models. In addition, it also showed some efficacy against breast cancer cells and neurodegenerative diseases like Alzheimer's and Parkinson's disease.
UK383367 works by inhibiting p38 MAP kinase, an enzyme that plays a crucial role in the inflammatory response of cells. By blocking this pathway, it can reduce inflammation and prevent further damage to the affected tissues. Furthermore, it can also cause cell cycle arrest and induce apoptosis in cancer cells. Researchers have hypothesized that UK383367 may also have neuroprotective properties by preventing neuronal death caused by oxidative stress or inflammation.
UK383367 inhibits the activity of p38 MAPK by binding to its ATP-binding site. This prevents the phosphorylation of downstream targets and the activation of pro-inflammatory cytokines such as TNFα, IL-1β, and IL-6. It also activates the Nrf2/ARE signaling pathway, which induces the expression of antioxidant enzymes and protects the cells from oxidative stress. In cancer cells, UK383367 can induce cell cycle arrest and apoptosis by regulating the expression of pro- and anti-apoptotic proteins.
The safety profile of UK383367 is still being evaluated in preclinical studies. However, it has been shown to be well-tolerated in animal models. Some adverse effects were reported, such as diarrhea, weight loss, and hematological abnormalities, but these were considered mild to moderate. Since UK383367 is not yet approved for human use, there is no data available on its safety in humans.
As mentioned above, UK383367 has been shown to cause mild to moderate adverse effects in animal models. These include diarrhea, weight loss, and hematological abnormalities. However, more research is needed to determine the full extent of its potential side effects in humans.
The dosing information for UK383367 is not yet established since it is still in the preclinical stage. The optimal dose, route of administration, and frequency of dosing will need to be determined in clinical trials before it can be used in humans.
UK383367 is a promising drug candidate with potential therapeutic applications in the treatment of inflammatory diseases, cancer, and neurodegenerative disorders. It works by inhibiting p38 MAP kinase, which is involved in various cellular processes such as inflammation, cell proliferation, differentiation, and apoptosis. Although it has shown health benefits in animal models, more research is needed to establish its safety and efficacy in humans